JAK inhibitors (class)
Drug timelines are a Plus or Pro feature.
2 regulatory and trial events tracked for JAK inhibitors (class), covering 2025-12-09 to 2026-03-23. Get the full timeline:
Most recent: Clinical Trial Update: A Prospective Cohort Study Evaluating the Efficacy and Safety of Guselkumab (GUS) With JAK Inhibitors in Patients With Difficult-To-Treat Inflammatory Bowel Disease (IBD)